Y0000377
利巴韦林
European Pharmacopoeia (EP) Reference Standard
别名:
1-β-D-呋喃核糖基-1,2,4-三唑-3-甲酰胺
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H12N4O5
化学文摘社编号:
分子量:
244.20
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
ribavirin
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
InChI
1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChI key
IWUCXVSUMQZMFG-AFCXAGJDSA-N
基因信息
human ... IMPDH1(3614)
正在寻找类似产品? 访问 产品对比指南
一般描述
嘌呤核苷酸生物合成中咪唑核苷酸中间体的类似物。
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Ribavirin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂。
用于抵御多种人类病毒感染的抗病毒剂，特别是慢性肝炎C、HIV 和腺病毒。其代谢产物利巴韦林 5′-磷酸，是肌苷一磷酸 (IMP) 脱氢酶的抑制剂，但也有实验证据支持许多其他作用机制。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
预防措施声明
危险分类
Muta. 2 - Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Tung-Hung Su et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(19), 7844-7849 (2013-04-25)
MicroRNA-122 (miR-122) facilitates hepatitis C virus replication in vitro. Serum miR-122 has been implicated as a biomarker for various liver diseases; however, its role in chronic hepatitis C remains unclear. To address this issue, 126 patients with chronic hepatitis C
Chen-Hua Liu et al.
Annals of internal medicine, 159(11), 729-738 (2013-12-04)
Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and
Fred Poordad et al.
The New England journal of medicine, 370(21), 1973-1982 (2014-04-15)
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir
Eric Druyts et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 56(7), 961-967 (2012-12-18)
A systematic review and meta-analysis were conducted to examine the efficacy and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) in children and adolescents with chronic hepatitis C virus (HCV). Medline, Embase, and Cochrane Central Register
M Colombo et al.
Gut, 63(7), 1150-1158 (2013-11-10)
Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-α (PEG-IFNα) and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持